Discover
AMLX
Amylyx Pharmaceuticals, Inc.
18.50
1 x 16.83
1 x 19.29
bid
ask
+
1.05
6.02%
22 @ 04:00 PM
18.55 +0.05 (0.27%)
| Ytd | 53.15% | |
| 1y | 125.33% |
17.38
day range
18.86
7.48
52 week range
19.15
| Open | 17.44 | Prev Close | 17.45 | Low | 17.38 | High | 18.86 | Mkt Cap | 1.54B |
| Vol | 2.72M | Avg Vol | 1.39M | EPS | -1.50 | P/E | -12.33 | Forward P/E | 2.77 |
| Beta | -0.20 | Short Ratio | 7.80 | Inst. Own | 105.33% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 15.57 | 200-d Avg | 14.61 | 1yr Est | 24.40 |
| Income Statement | |||
| Operating Expenses | 43.78M | ||
| Research and Development Expense | 27.61M | ||
| Selling, General and Administrative Expense | 16.17M | ||
| Operating Income | -43.78M | ||
| Net Income | -41.28M | ||
| Net Income Common Stock | -41.28M | ||
| Net Income Common Stock (USD) | -41.28M | ||
| Consolidated Income | -41.28M | ||
| Earnings per Basic Share | -0.37 | ||
| Earnings per Basic Share (USD) | -0.37 | ||
| Earnings per Diluted Share | -0.37 | ||
| Earning Before Interest & Taxes (EBIT) | -41.28M | ||
| Earning Before Interest & Taxes (USD) | -41.28M | ||
| Weighted Average Shares | 110.56M | ||
| Weighted Average Shares Diluted | 110.56M | ||
| Balance Sheet | |||
| Cash and Equivalents | 230.12M | ||
| Cash and Equivalents (USD) | 230.12M | ||
| Investments | 50.63M | ||
| Investments Current | 50.63M | ||
| Current Assets | 285.02M | ||
| Property, Plant & Equipment Net | 5.09M | ||
| Total Assets | 293.60M | ||
| Debt Current | 1.16M | ||
| Total Debt | 5.63M | ||
| Current Liabilities | 15.97M | ||
| Debt Non-Current | 4.48M | ||
| Total Liabilities | 20.44M | ||
| Accumulated Retained Earnings (Deficit) | -792.71M | ||
| Accumulated Other Comprehensive Income | 240.00K | ||
| Shareholders Equity | 273.16M | ||
| Shareholders Equity (USD) | 273.16M | ||
| Assets Non-Current | 8.58M | ||
| Total Debt (USD) | 5.63M | ||
| Liabilities Non-Current | 4.48M | ||
| Trade and Non-Trade Payables | 3.53M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 98.00K | ||
| Net Cash Flow from Financing | 3.22M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 2.49M | ||
| Net Cash Flow - Business Acquisitions and Disposals | -4.00M | ||
| Issuance (Purchase) of Equity Shares | 7.16M | ||
| Net Cash Flow from Investing | 36.26M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 40.26M | ||
| Net Cash Flow from Operations | -36.88M | ||
| Effect of Exchange Rate Changes on Cash | -111.00K | ||
| Share Based Compensation | 6.12M | ||